FOURKITES
29.2.2024 13:31:30 CET | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites today published its global Premier Carrier List (PCL), recognising the growing community of brokers, carriers and 3PLs who are achieving the highest standards of visibility-related operational excellence across all modes of transport. Carriers featured on FourKites’ PCL deliver high-quality and consistent shipment data, facilitating faster turnaround times and optimised performance for shippers and carriers alike.
FourKites’ latest data reaffirms the importance of providing market-leading shipment visibility to customers, highlighting outsized growth amongst members of the Premier Carrier List. For instance, FourKites’ data indicates that new carriers who qualified for the PCL in H2 2023 saw an 11% month-over-month increase in shipment volume in the second half of 2023 compared to the overall network average. Further, the data shows that carriers on the PCL have approximately 4.5 times more shipper customers than non-PCL carriers. The H2 PCL list includes 750+ carriers, representing a 7% increase from the first half of 2023. Notably, the number of premier carriers offering service in Europe grew by 21% since the first half of 2023.
“We’re delighted to be named to FourKites’ Premier Carrier List,” said Stefan Barten, Global Key Account Manager for Gebrüder Weiss GmbH, a leading transportation company in Europe. “FourKites helps us spend less time managing administrative tasks and more time booking high-paying quality freight.”
“At Van den Bosch, we believe the significance of data lies in its swift accessibility and immediate utilisation”, says Twan Slits, Manager IT, Van den Bosch. “With the assistance of the FourKites team, we can provide our customers with precise real-time data regarding the whereabouts of their shipments and their anticipated arrival times. This is a vital part of our innovative and future-proof supply chain solutions, and we are happy to be named to the FourKites Premier Carrier List.”
The findings from FourKites’ latest PCL run in parallel with early indications that freight sector recovery may lie ahead in 2024. FreightWaves’ Freight Sentiment Index shows cautious optimism about recovery among carriers, as well as strong year-over-year improvements in expectations for long-term profitability. In addition, DAT Freight & Analytics recently reported a 61% increase in the flatbed load-to-truck ratio from December 2023 to January 2024, commonly interpreted as a leading signal of impending rate changes.
“We may now be looking at the bottom of the freight market,” says Jason Eversole, VP of Professional Services Solutions at FourKites. “As carriers and brokers emerge from a difficult market looking toward the future, it’s important to note that shippers have also evolved and changed their expectations during this time. Over the past 18 months, shippers have been in a strong position and demanded visibility. Many carriers adapted to meet those expectations in tracking quality and service to survive, and visibility became more important than ever. As the market recovers, carriers that deliver value by providing visibility will be best-positioned to win business with high-quality shippers and grow.”
FourKites’ latest Premier Carrier List is accessible here, where users can search based on carrier capabilities, transportation modes, serviced geographies and other relevant criteria.
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229103552/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom